RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

Article Details

Citation
Copy to clipboard

Materna V, Stege A, Surowiak P, Priebsch A, Lage H

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

Biochem Biophys Res Commun. 2006 Sep 15;348(1):153-7. Epub 2006 Jul 14.

PubMed ID
16876126 [ View in PubMed
]
Abstract

The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel. To overcome the ABCC2-depending drug resistance, two specific anti-ABCC2 small interfering RNAs (siRNAs) were designed for transient triggering of the gene-silencing RNA interference (RNAi) pathway in the cisplatin-resistant human ovarian carcinoma cell line A2780RCIS. Since both siRNAs showed biological activity, for stable inhibition of ABCC2 a corresponding short hairpin RNA (shRNA)-encoding expression vector was designed. By treatment of A2780RCIS cells with this construct, the expressions of the targeted ABCC2 encoding mRNA and transport protein were inhibited. These effects were accompanied by reversal of resistance against cisplatin and paclitaxel. Thus, the data demonstrate the utility of the analyzed RNAs as powerful laboratory tools and indicate that siRNA- and shRNA-mediated RNAi-based gene therapeutic approaches may be applicable in preventing and reversing ABCC2-depending drug resistance.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
ATPATP-binding cassette sub-family G member 1ProteinHumans
Unknown
Not AvailableDetails
ATPCanalicular multispecific organic anion transporter 1ProteinHumans
Unknown
Not AvailableDetails